First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The transaction is expected to close in Q2 FY 2026
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Subscribe To Our Newsletter & Stay Updated
